Blog Posts - Genotype 3



Merck Announces Presentation of Phase 2 Clinical Trial Results of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir at the International Liver Congress™ 2015

Results of C-SALVAGE Study Showed High Sustained Virologic Response Rates in Patients Who Failed Prior Combination Therapy with Certain Direct Acting Antiviral (DAA) Agents Results of C-SWIFT Study Provide Proof-of-Concept for Shorter Than Twelve We...
by Hepatitis C Research and News on Apr 25, 2015

ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)

97% of post-transplant patients with HCV genotype 1a achieved cure 91% of post-transplant patients with HCV genotype 3 achieved cure  No need seen to alter existing transplantation medication regimens Saturday, April 25, 2015 10:00 am EDT...
by Hepatitis C Research and News on Apr 25, 2015

Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5

-- High Cure Rates Observed Across a Range of Genotypes -- VIENNA, Austria--(BUSINESS WIRE)--Apr. 25, 2015-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from two studies evaluating the safety and efficacy of investigational uses of...
by Hepatitis C Research and News on Apr 25, 2015

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

Hepatology Volume 61, Issue 4 April 2015 Pages 1127–1135 David R. Nelson, James N. Cooper, Jacob P. Lalezari, Eric Lawitz, Paul J. Pockros, Norman Gitlin, Bradley F. Freilich, Ziad H. Younes, William Harlan, Reem Ghalib, Godson Oguchi, P...
by Hepatitis C Research and News on Apr 23, 2015

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

Hepatology. 2015 Apr;61(4):1127-35. doi: 10.1002/hep.27726. Epub 2015 Mar 10 Nelson DR1, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Berns...
by Hepatitis C Research and News on Apr 10, 2015

Bristol-Myers Squibb Announces Acceptance of New Drug Application for Investigational Daclatasvir for FDA Review for the Treatment of Hepatitis C Genotype 3

The NDA contains data to support approval for daclatasvir in combination with sofosbuvir; would be the first 12-week regimen specifically for the treatment of hepatitis C genotype 3 The application is based on a Phase III clinical trial which tested...
by Hepatitis C Research and News on Mar 19, 2015

ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients

Daclatasvir+sofosbuvir regimen achieves SVR12 in 90% of treatment-naïve and 86% of treatment-experienced genotype 3 patients ALLY-3 is the first Phase 3 study of an all-oral, ribavirin-free treatment regimen for genotype 3 HCV patients with a 12-we...

My Treatment Approach to Chronic Hepatitis C Virus (Genotypes 1–6)

Article in Press Mitchell L. Shiffman, MD, April G. Long, NP, Amy James, FNP, Phillip Alexander, NP Published Online: May 24, 2014 DOI: http://dx.doi.org/10.1016/j.mayocp.2014.04.013 Publication stage: In Press Corrected Proof...
by Hepatitis C Research and News on Jun 14, 2014

Single-Pill HCV Combo Shines With Older Drug

Published: Apr 10, 2014 By Michael Smith, North American Correspondent, MedPage Today Reviewed by F. Perry Wilson, MD, MSCE; Instructor of Medicine, Perelman School of Medicine at the University of Pennsylvania Action Points Note that t...
by Hepatitis C Research and News on Apr 10, 2014

Gilead Announces Phase 2 Results for Two Investigational All-Oral Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C

-- Data Support Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination with Ribavirin in Genotype 3 HCV; Product Under Regulatory Review for Genotype 1 in U.S., Europe -- -- Combination of Sofosbuvir and GS-5816 Demonstrates Efficacy Against HCV...
by Hepatitis C Research and News on Apr 10, 2014

Gilead Announces Results from Study of Sovaldi® for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy

-- Results Demonstrate Efficacy of Sovaldi-Based Regimen in GT1 Infected Patients Who Failed Prior Therapy with Other Direct Acting Antivirals-- -- Data Support Retreatment with Sovaldi-Based Regimen in GT2 or GT3 Infected Patients Who Failed Prior...
by Hepatitis C Research and News on Apr 10, 2014

Regimens Containing Gilead's Sovaldi Have Major Advantages over Other Therapies for Hepatitis C Virus Genotype-3

Gastroenterologists Would Prescribe Sovaldi plus Daclatasvir plus Ribavirin to 60 Percent of Their Genotype-3 Patients, According to Findings from Decision Resources Group BURLINGTON, Mass., April 1, 2014 /PRNewswire/ -- Decision Resources Group fin...

Metabolic syndrome is associated with poor treatment response to antiviral therapy in chronic hepatitis C genotype 3 patients

Eur J Gastroenterol Hepatol. 2014 Mar 17. [Epub ahead of print] Aziz H1, Gill U, Raza A, Gill ML. Abstract INTRODUCTION: Hepatitis C viral (HCV) infection is caused by an RNA virus. HCV infection is considered to induce systemic disease that cause...
by Hepatitis C Research and News on Mar 22, 2014

Review article: HCV genotype 3 – the new treatment challenge

Alimentary Pharmacology & Therapeutics Volume 39, Issue 7, pages 686–698, April 2014 Review Article You have free access to this content J. Ampuero1,2, M. Romero-Gómez1 and K. R. Reddy2,* Article first published online: 20 FEB 2014 DOI:...
by Hepatitis C Research and News on Mar 16, 2014

HCV Genotype 3 is Associated with an Increased Risk of Cirrhosis and Hepatocellular Cancer in a National Sample of U.S. Veterans with HCV

Hepatology Accepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.) Research Article Fasiha Kanwal1,2,*, Jennifer R. Kramer1,3,  Jawad Ilyas2, Zhigang D...
by Hepatitis C Research and News on Feb 26, 2014

HCV Genotype 3

Provided by NATAP Written by Jules Levin You are asking if Sovaldi (sofosbuvir) is effective for patients with genotype 3 with compensated cirrhosis??? Here is the data below from studies showing 83%+ SVR rates with Sovaldi+Peg/Rbv having better r...
by Hepatitis C Research and News on Feb 22, 2014

Sofosbuvir Plus Ribavirin Cures Over 90% of Treatment-Naive Patients With HCV Genotype 3 – CDDW 2014

Presented at CDDW Tags: Hepatitis, ribavirin, sofosbuvir By Thomas S. May TORONTO -- February 11, 2014 -- A 24-week course of ribavirin plus sofosbuvir resulted in sustained virologic response rates 12 weeks after treatment (SVR12) in over 90% of...
by Hepatitis C Research and News on Feb 12, 2014

Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection (Full Text)

Provided by NATAP Download the PDF here Download the PDF here N Engl J Med January 16, 2014 "We assessed daclatasvir plus sofosbuvir in untreated patients and patients in whom previous treatment with telaprevir or boceprevir had failed. Over...
by Hepatitis C Research and News on Jan 19, 2014

Clinical Trial: A Phase III Evaluation of Daclatasvir + Sofosbuvir in Genotype 1-6 Chronic HCV Subjects With Cirrhosis Who May Require Future Liver Transplant and Subjects Post-Liver Transplant

This study is not yet open for participant recruitment. Verified January 2014 by Bristol-Myers Squibb Sponsor: Bristol-Myers Squibb Information provided by (Responsible Party): Bristol-Myers Squibb ClinicalTrials.gov Identifier: NCT02032875 F...
by Hepatitis C Research and News on Jan 11, 2014

Clinical Trial: Phase III Daclatasvir + Sofosbuvir for Genotype 3 Chronic HCV (ALLY 3)

This study is not yet open for participant recruitment. Verified January 2014 by Bristol-Myers Squibb Sponsor: Bristol-Myers Squibb Information provided by (Responsible Party): Bristol-Myers Squibb ClinicalTrials.gov Identifier: NCT02032901 F...
by Hepatitis C Research and News on Jan 11, 2014


Trending Topics

Close